Medically Associated Science and Technology Program, Cedars-Sinai Medical Center, Los Angeles, CA; Geffen School of Medicine, University of California, Los Angeles. Email:
Am J Manag Care. 2018 Jan;24(3 Suppl):S35-S46.
Irritable bowel syndrome (IBS), a complex disorder of the gastrointestinal tract, is characterized by abdominal pain associated with defecation or changes in stool form or frequency. IBS is associated with substantial burden, including direct medical costs and indirect costs. Direct costs associated with IBS in the United States have been estimated to exceed $1 billion. However, indirect costs, such as negative effect on quality of life (QOL) and work productivity, are difficult to quantify. There are 3 main subtypes: IBS with prominent diarrhea (IBS-D), IBS with constipation, and IBS with mixed symptoms of both constipation and diarrhea. A number of pharmacologic agents have been used to treat IBS-D despite lack of approval by the FDA for this indication. The pharmacologic agents that are indicated by the FDA for the treatment of IBS-D include alosetron, eluxadoline, and rifaximin. The negative impact of IBS-D symptoms on QOL reported by patients indicate there is an unmet need for therapies that effectively treat and manage the symptoms of this condition. Addressing gaps in treatment is an important priority.
肠易激综合征（IBS）是一种复杂的胃肠道疾病，其特征是腹痛与排便相关，或伴有粪便形态或频率改变。IBS 会造成沉重负担，包括直接医疗费用和间接费用。据估计，美国 IBS 的直接费用超过 10 亿美元。然而，间接费用（如对生活质量和工作生产力的负面影响）则难以量化。IBS 有 3 种主要亚型：腹泻为主型肠易激综合征（IBS-D）、便秘为主型肠易激综合征和便秘与腹泻混合症状型肠易激综合征。尽管 FDA 尚未批准这些适应证，但仍有许多药物被用于治疗 IBS-D。FDA 批准用于治疗 IBS-D 的药物包括阿洛司琼、鲁比前列酮和利福昔明。IBS-D 症状对患者生活质量的负面影响表明，对于有效治疗和管理该疾病症状的疗法存在未满足的需求。解决治疗中的差距是一个重要的优先事项。
